Abstract
AbstractIn a clinical contest, it is common to use dedicated phantoms to perform quality assurance test to check the performance of a SPECT system. Some of these phantoms are also used to calibrate the system for dosimetric evaluation of patients undergoing radiometabolic cancer therapy. In this work, a 3D-OSEM reconstructed 177Lu SPECT dataset of a homogeneous cylindrical phantom is described. This dataset was acquired to investigate the variation of the SPECT calibration factor, counts convergence, noise and uniformity by varying the number of subsets and iterations. In particular, the dataset is composed of images reconstructed using five different numbers of subsets and sixteen different numbers of iterations, for a total of 80 different configurations. The dataset is suitable for comparison with other reconstruction algorithms (e.g. FBP, MLEM, etc.) and radionuclides (e.g. technetium, yttrium). In regards to the uniformity issue, the same dataset allows the user to perform radiomic investigations on the influence of the border effect on the reconstructed images.
Publisher
Springer Science and Business Media LLC
Subject
Library and Information Sciences,Statistics, Probability and Uncertainty,Computer Science Applications,Education,Information Systems,Statistics and Probability
Reference31 articles.
1. Dash, A., Chakraborty, S., Pillai, M. R. & Knapp, F. F. Jr. Peptide receptor radionuclide therapy: an overview. Cancer Biother Radiopharm. 30, 47–71 (2015).
2. Molina Trinidad, E. M. & Salas Casas, A. Somatostatine analogs, how biomarkers in the diagnostic and treatment for cancer and others damages. Int J Pharm Sci Rev Res. 27, 31–46 (2014).
3. Otte, A. et al. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet. 351, 417–8 (1998).
4. Marincek, N. et al. Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of phase I dose escalation study. J Transl Med. 15, 11–17 (2013).
5. Paganelli, G. et al. 177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study. Eur J Nucl Med Mol Imaging. 41, 1845–1851 (2014).